AbbVie Inc. (ABBV)
5 Dividend ETFs That Could Pay You for Life
Whether you're just beginning to invest or sailing into retirement, you can benefit from a lifetime stream of passive income.
AbbVie Lifts Profit Outlook as Sales Rise
AbbVie raised its full-year adjusted earnings outlook, even though profit was pressured by increased expenses during the third quarter.
AbbVie lifts annual profit forecast on resilient demand for newer immunology drugs
AbbVie raised its 2025 profit forecast on Friday, after strong sales of newer immunology drugs Skyrizi and Rinvoq helped boost third-quarter results above Wall Street estimates.
AbbVie: Deep Discount Before Earnings
AbbVie Inc. is reiterated as a Strong Buy ahead of Q3 earnings, with revenue growth expected to outpace the sector median. ABBV consistently delivers double beats, maintains robust FCF margins, and is investing aggressively in R&D for future growth. The DDM model suggests ABBV is significantly undervalued, with a fair value estimate indicating 27% upside potential over the next year.
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.
AbbVie Up More Than 30% in 6 Months: How to Play the Stock
AbbVie's 30% surge in six months is powered by booming sales of Skyrizi and Rinvoq and renewed strength across oncology and neuroscience.
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
This 3 Stocks Portfolio Provides Monthly Income
Who doesn't like payday? Investors can structure a portfolio that provides monthly income with this combination of three stocks.
Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings
ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.
AbbVie: "Strong Buy" On Rinvoq Expansions And Immunology Pipeline Addition
AbbVie earns a Strong Buy rating in my book, driven by Rinvoq's label expansions and robust immunology pipeline growth. ABBV achieved FDA approval for Rinvoq in giant cell arteritis and reported strong phase 3 results for severe alopecia areata, supporting long-term revenue growth. The acquisition of Capstan Therapeutics brings CPTX2309, a first-in-class tLNP CAR-T candidate, potentially transforming B-cell autoimmune disorder treatment landscape.
AbbVie (ABBV) Stock Falls Amid Market Uptick: What Investors Need to Know
The latest trading day saw AbbVie (ABBV) settling at $226.22, representing a -1.27% change from its previous close.
Can Rinvoq and Skyrizi Sales Drive Another Strong Quarter for AbbVie?
ABBV leans on booming Skyrizi and Rinvoq-driven sales to sustain growth and counter Humira's decline as Q3 results approach.
